Table 1

Characteristics of selected trials

Author (year)

Trial name

Participants

Sample size

Mean age at baseline (year)

Current smoker (%)

Male (%)

Follow-up (year)

Aspirin dose (mg/day)


Ridker et al [26] (2005)

Women's Health Study (WHS)

Healthy women ≥ 45 years in USA

39 876

55

13

0

10.0

100†

de Gaetano [19] (2001)

Primary Prevention Project (PPP)

Patients with at least one of the major recognized cardiovascular risk factors in Italy

4 495

64

15

42

3.6

100

Cote et al [18] (1995)

Asymptomatic Cervical Bruit Study (ACBS)

Patients with asymptomatic carotid stenosis in Canada

372

67

37

45

2.3

325

ETDRS Study Group [13] (1992)

Early Treatment Diabetic Retinopathy Study report (ETDRS)

Patients with a clinical diagnosis of diabetes mellitus

3 711

18–70

44#

52

5.0

650

Juul-Moller et al [24] (1992)

Swedish Angina Pectoris Aspirin Trial (SAPAT)

Patients with chronic stable angina

2 035

67

16

52

4.2

75

Hansson et al [23] (1998)

Hypertension Optimal Treatment Study (HOT)

Patients with hypertension and diastolic blood pressure between 100 mmHg and 115 mmHg from countries in Europe, America, and Asia

18 790

62

16

53

3.8

75

Swedish cooperative [8] (1987)

Swedish Cooperative Study (Swedish Coop)

Patients with cerebral infarction, minor or major stroke

505

68

52

62

2.0

1 500

EAFT Study Group [14] (1993)

European Atrial Fibrillation Trial (EAFT)

Patients with non-rheumatic atrial fibrillation

782*

73

19

63

2.3

300

SALT Collaborative Group [11] (1991)

Swedish Aspirin Low-Dose Trial (SALT)

Patients after transient ischaemic attack (TIA) or minor stroke

1 360

67

25

66

2.7

75

Cairns et al [17] (1985)

Canadian multicenter trial (Canadian)

Patients with unstable angina who were hospitalized in coronary care units in Canada

278*

57

35

70

1.5

1 300

Stroke Prevention in Atrial Fibrillation Study group [12] (1991)

Stroke Prevention in Atrial Fibrillation Study (SPAF)

Patients with constant or intermittent atrial fibrillation

1 120*

67

16

71

1.3

325

Sorensen et al [27] (1983)

A Danish cooperative study (Danish Coop)

Patients experienced at least one reversible cerebral ischemic attack

203

59

24¶

73

2.0

1 000

Farrell et al [22] (1991)

United Kingdom transient ischaemic attack aspirin trial (UK-TIA)

Patients with a transient ischaemic attack or minor ischaemic stroke

2 435

60

53

73

4.0

300/1 200

Persantine-Aspirin Reinfarction Study Research Group [5] (1980)

Persantine-aspirin Reinfarction Study (PARIS)

Patients recovered from myocardial infarction

1 216*

56

27

77

3.4

972

Breddin et al [16] (1980)

German-Austrian aspirin trial (GAAT)

Patients who had survived a myocardial infarction for 30–42 days

626

45–70

58

78

2.0

1 500

Elwood and Sweetnam [21] (1979)

Aspirin and secondary mortality after myocardial infarction (Cardiff-II)

Patients with confirmed myocardial infarction

1 725‡

56

60

85

1.0

900

AMIS Study Group [6] (1980)

Aspirin myocardial infarction study (AMIS)

Patients experienced at least one myocardial infarction in USA

4 524

55

27

89

3.0

1 000

Elwood et al [20] (1974)

Secondary prevention of mortality from myocardial infarction (Cardiff-I)

Patients with recent myocardial infarction

1 239‡

55

NA

100

1.1

300

Coronary Drug Project Research Group [7] (1980)

Coronary Drug Project Aspirin Study (CDPA)

Patients with a history of myocardial infarction

1 529‡

NA

NA

100

1.8

324

Lewis et al [25] (1983)

Veterans Administration Cooperative Study (VACS)

Patients with unstable angina in USA

1 266

56

50

100

1.0

324

Steering Committee of the Physicians' Health Study Research Group [9] (1989)

Physicians' Health Study (PHS)

Healthy male physicians in USA

22 071

52

11

100

5.0

325†

The RISC Group [10] (1990)

Research Group on Instability in Coronary Artery Disease (RISC)

Men with unstable coronary artery disease in Southeast Sweden

796*

58

38

100

1.0

75

Medical Research Council's General Practice Research Framework Group [15] (1998)

Thrombosis prevention Trial (TPT)

Patients at high risk of cardiovascular disease in UK

2 540

58

41

100

4.0

75


NA: not available.

*Only the participants in placebo group and aspirin group were included.

† Every other day.

‡ Data are from [4].

¶ > 15 cigarettes/day.

# ≥ 6 cigarettes/day.

Yerman et al. BMC Medicine 2007 5:29   doi:10.1186/1741-7015-5-29

Open Data